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HAART in terms of effectiveness and cost, in a sample of
HIV patients representative of those currently treated.
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Lafuma A1, Fagnani F1, Berdeaux G2
1Cemka SA, Bourg-la-Reine, France; 2Alcon SA, Rueil-
Malmaison, France
OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of a fixed topical combination of cipro-
floxacin and hydrocortison (CH) with a fixed topical com-
bination of polymixin neomycin and hydrocortison (PNH)
in the treatment of acute otitis externa (AOE), in France.
METHODS: Two randomized controlled clinical trials
were conducted comparing the clinical failure rate of
ciprofloxacin alone with CH and PNH: one in Europe
(682 patients of whom 242 were French) and the other in
the USA (728 patients). The resource utilization and cost
of clinical failure were estimated from a French panel of
ENT specialists and GPs. A model was constructed to sim-
ulate the current management of PNH and CH in France.
Sensitivity analyses were conducted using estimates from
each study and from the pooled analysis. Two perspectives
were considered: societal and third party payer. RESULTS:
The probability to have a bacterial failure was 2.4 lower
(pooled analysis; P  0.0001) in the ciprofloxacin-treated
patients whose infection was documented with Pseudomo-
nas Aeruginosa (2/3 of species). The clinical failure rate
was 1.9 lower (pooled analysis; P  0.05) in the same pa-
tients while no difference was found on the other species.
Second line therapy included a bacteriological sample
(21%), an oral antibiotic (92%) and an anti-inflammatory
agent (50%), at a mean cost of 107€. Clinical failure rate
estimated by the model was 6.6% with CH and 9.3% with
PNH. The incremental cost of CH over PNH, due to its
better efficacy, was 5.25€ according to the third party
payer perspective and 7.20€ according to the society.
CONCLUSION: Because ciprofloxacin is more effective on
Pseudomonas Aeruginosa, the most often encountered
species in AOE, a fixed combination of ciprofloxacin and
hydrocortisone allows to reduce the clinical failure rate
and its cost, in comparison to PNH.
Mean cost per
patient-year HAART CONTROL COST P value
ART 35 695 13 156 171 0.0001
Other treatments 16 490 43 092 62 0.0560
Hospital 32 136 42 790 25 0.3736
Total 84 321 99 038 15 0.4597
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OBJECTIVES: To investigate the impact of patient com-
pliance on cost-effectiveness of the following oral anti-
bacterials in in-patient treatment of mild to moderate su-
perficial skin and soft-tissue (SST) infections from the
perspective of hospitals in Germany: amoxicillin/clavu-
lanic acid 500/125 mg thrice daily (AMC); cefpodoxime
proxetil 200mg twice daily (CPD); cefuroxime axetil
500mg twice daily (CXM); ciprofloxacin 500mg twice
daily (CIP); or roxithromycin 300mg once daily (ROX).
METHODS: An economic model was used to quantify
the cost-effectiveness ratio (CER) cost per successfully
treated patient of each alternative, based on decision-tree
technique synthesizing published data, the results of a
hospital survey and expert knowledge. Costs were exclu-
sively those incurred by hospitals. The method of the to-
tal differential then was used to quantify the impact of
the respective compliance rate on the CER of each alter-
native based on average values of the model parameters.
RESULTS: There were 3 groups of CERs: 105 DM (ROX)
with once, between 175 and 193 DM (CXM, CPD, CIP)
with twice, and 265 DM (AMC) with thrice daily appli-
cation. The application-specific compliance rate had by
far the greatest impact on each CER. This impact was
about 1.5- to 3-fold of that of the clinical effectiveness
and about 1.9- to 4.7-fold of that of the acquisition cost
per unit of each alternative. In the sensitivity analysis, the
robustness of the model was shown in a Monte Carlo
simulation. After 10,000 computations each, the cost-
effectiveness acceptability curves of the alternatives again
showed 3 distinct groups. Once daily application (ROX)
with the highest compliance rate was most favourable
followed by twice (CXM, CPD, CIP) and thrice (AMC)
daily application with moderate and low compliance, re-
spectively. CONCLUSIONS: Choosing an alternative as-
sociated with high compliance or improving patient com-
pliance highlights an important saving potential for hospitals
in the treatment of SST infections.
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OBJECTIVES: To evaluate the practice and conduct eco-
nomic analysis of antibiotic prophylaxis (ABP) in intra-
